LJPC 501

Drug Profile

LJPC 501

Alternative Names: Angiotensin-II - LJPC; LJPC501

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator La Jolla Pharmaceutical Company
  • Class Neuropeptides; Oligopeptides; Peptide hormones; Vasoconstrictors
  • Mechanism of Action Angiotensin receptor agonists; Galectin modulators; Sodium-hydrogen antiporter modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Hypotension
  • Discontinued Hepatorenal syndrome

Most Recent Events

  • 25 Sep 2017 La Jolla intends to submit a Marketing Authorization Application to European Medicines Agency for Hypotension in the third quarter of 2018
  • 25 Sep 2017 The European Medicines Agency’s Committee for Medicinal Products for Human Use issues favourable Scientific Advice for the EU regulatory pathway for LJPC-501 for the treatment of Hypotension
  • 20 Sep 2017 Efficacy data from the phase III ATHOS-3 trial in Hypotension released by La Jolla Pharmaceutical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top